logo
Susan G. Komen Deeply Concerned About Proposed Cuts in FY26 Federal Budget Proposal

Susan G. Komen Deeply Concerned About Proposed Cuts in FY26 Federal Budget Proposal

Business Wire02-05-2025

WASHINGTON--(BUSINESS WIRE)-- Susan G. Komen®, the world's leading breast cancer organization, is deeply alarmed by the Trump Administration's budget proposal for fiscal year 2026 (FY26) which would eliminate all funding for critical cancer prevention and control programs, including the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), and significantly cut life-saving research at the Department of Health and Human Services (HHS), including the National Institutes of Health (NIH).
An estimated 319,750 people in the United States will be diagnosed with breast cancer and nearly 43,000 will die from the disease this year alone.
An estimated 319,750 people in the United States will be diagnosed with breast cancer and nearly 43,000 will die from the disease this year alone. Regular screening enables us to detect potential cancers at earlier stages and refer patients to further care, often yielding better outcomes for patients and resulting in decreased financial pressure on our healthcare system.
Congress established NBCCEDP which assists individuals with low-incomes and no or inadequate insurance gain access to breast and cervical cancer screening and diagnostic services that are free or low-cost. For over 30 years, NBCCEDP funded programs have served more than 6.4 million people and provided more than 16.5 million breast and cervical cancer screening examinations. To date, NBCCEDP has diagnosed over 79,000 invasive breast cancers, over 25,000 premalignant breast lesions, more than 5,000 invasive cervical cancers, and over 248,000 premalignant cervical lesions. Without access to early detection programs, many people who are uninsured are forced to delay or forgo screenings, which could lead to late-stage breast cancer diagnoses. This delay can mean that a person may not seek care until the cancer has spread beyond the breast, making it up to five times more expensive, harder to treat, and more likely to result in poor outcomes.
Investment in early detection is an investment in not just the patient's future but a more efficient healthcare system. Unfortunately, the President's FY26 budget proposal does not invest in the American people's fight against breast cancer. The budget proposal would end federal funding for NBCCEDP in addition to other incredibly important programs to the cancer community, including the National Program of Cancer Registries, the National Comprehensive Cancer Control Program, and the Colorectal Cancer Control Program. If adopted, the FY26 budget proposal will set the cancer screening and detection back decades and result in increased deaths from cancer.
In addition to proposing to eliminate NBCCEDP funding, the proposal would decimate investment in medical research at the NIH. Biomedical research has been the driving force behind decades of advances that have improved the health of people in every corner of America – including the lives of those affected by breast cancer, leading to new and better cures, diagnostics, and preventive interventions – and has positioned the United States as the global leader in biomedical breakthroughs, the development of new technologies, and innovative treatments. Additionally, NIH research funding helps fuel economic growth— every dollar invested by the NIH in research generates $2.56 in new economic activity. Alarmingly, proposed cuts are already prompting top scientific talent to consider careers outside the U.S. Put simply, cuts of this magnitude to NIH are shortsighted for both the American healthcare system and the economy.
Komen urges Congress to work in a bicameral, bipartisan manner to fund the federal government with robust investments in our nation's health. While we support a healthcare and public health system that works efficiently and effectively for everyone—slashing funding across HHS is dangerous and will harm the breast cancer community. Federal investments in early detection and research are not just compassionate—they are practical, cost-effective, and essential to the health of the nation.
Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Yahoo

time2 hours ago

  • Yahoo

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Business Wire

time3 hours ago

  • Business Wire

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit

Palestinians say Israeli fire kills 12 near aid sites
Palestinians say Israeli fire kills 12 near aid sites

Boston Globe

time3 hours ago

  • Boston Globe

Palestinians say Israeli fire kills 12 near aid sites

Advertisement Eleven of the latest bodies were brought to Nasser Hospital in the southern city of Khan Younis. Palestinian witnesses said Israeli forces fired on some at a roundabout around a kilometer (half-mile) from a site run by the Gaza Humanitarian Foundation, or GHF, in nearby Rafah. Israel's military said it fired warning shots at approaching 'suspects' who ignored warnings to turn away. It said the shooting happened in an area that is considered an active combat zone at night. Al-Awda Hospital said it received the body of a man and 29 people who were wounded near another GHF aid distribution point in central Gaza. The military said it fired warning shots in the area at around 6:40 a.m., but didn't see any casualties. Advertisement A GHF official said there was no violence in or around its distribution sites, all three of which delivered aid on Sunday. The group closed them temporarily last week to discuss safety measures with Israel's military and has warned people to stay on designated access routes. The official spoke on condition of anonymity in line with regulations. The new aid hubs are set up inside Israeli military zones where independent media have no access. The GHF also said it was piloting direct delivery to a community north of Rafah. Witnesses said the first shootings in southern Gaza took place at around 6 a.m., when they were told the site would open. Many headed toward it early, seeking desperately needed food before crowds arrived. Gaza's roughly 2 million Palestinians are almost completely reliant on international aid because nearly all food production capabilities have been destroyed. Adham Dahman, who was at Nasser Hospital with a bandage on his chin, said a tank fired toward them. 'We didn't know how to escape,' he said. 'This is [a] trap for us, not aid.' Zahed Ben Hassan said someone next to him was shot in the head. 'They said it was a safe area from 6 a.m. until 6 p.m. ... So why did they start shooting at us?' he said. 'There was light out, and they have their cameras and can clearly see us.' The military announced on Friday that the sites would be open during those hours, and the areas would be a closed military zone the rest of the time. Children cried over their father's body at the hospital. 'I can't see you like this, Dad!' one girl said. Advertisement The new aid hubs are run by GHF, a new group of mainly American contractors. Israel wants it to replace a system coordinated by the United Nations and international aid groups. Israel and the United States accuse the Hamas militant group of stealing aid. The UN denies there is systematic diversion. The UN says the new system is unable to meet mounting needs, allows Israel to use aid as a weapon by determining who can receive it and forces people to relocate to where aid sites are positioned. The UN system has struggled to deliver aid, even after Israel eased its blockade of Gaza last month. UN officials say their efforts are hindered by Israeli military restrictions, the breakdown of law and order and widespread looting. Experts warned earlier this year that Gaza was at critical risk of famine, if Israel didn't lift its blockade and halt its military campaign. Both were renewed in March. Israeli officials have said the offensive will continue until all hostages are returned and Hamas is defeated or disarmed and sent into exile. On Sunday, Israel's military invited journalists into Khan Younis to show a tunnel under the European Hospital, saying they found the body of Mohammed Sinwar, the head of Hamas' armed wing, there after he was killed last month. Israel has barred international journalists from entering Gaza independently since the war began. '(Israeli forces) would prefer not to hit or target hospitals,' army spokesperson Brig. Gen. Effie Defrin said. Sinwar's body was found in a room under the hospital's emergency room, Defrin said. Hamas has said it will only release the remaining hostages in return for Palestinian prisoners, a lasting ceasefire and an Israeli withdrawal from Gaza. Talks mediated by the U.S., Egypt, and Qatar have been deadlocked for months. Advertisement Hamas started the war with its attack on southern Israel on Oct. 7, 2023, when Palestinian militants killed around 1,200 people, mostly civilians, and took another 251 hostage. They still hold 55 hostages, fewer than half of them alive, after most of the rest were released in ceasefire agreements or other deals. Israel's military campaign has killed more than 54,800 Palestinians, according to Gaza's Health Ministry. It says women and children make up most of the dead, but doesn't say how many civilians or combatants were killed. Israel says it has killed more than 20,000 militants, without providing evidence. The war has destroyed vast areas of Gaza and displaced around 90 percent of its population.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store